Jeil Pharma Holdings Statistics

Total Valuation

Jeil Pharma Holdings has a market cap or net worth of KRW 121.73 billion. The enterprise value is 329.83 billion.

Market Cap	121.73B
Enterprise Value	329.83B

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Jeil Pharma Holdings has 15.35 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	15.35M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	76.13%
Owned by Institutions (%)	0.02%
Float	2.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.16
PB Ratio	0.37
P/TBV Ratio	0.44
P/FCF Ratio	11.04
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.95
EV / Sales	0.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	29.93

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.35.

Current Ratio	1.01
Quick Ratio	0.65
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	13.91
Interest Coverage	-1.48

Financial Efficiency

Return on equity (ROE) is -14.47% and return on invested capital (ROIC) is -1.42%.

Return on Equity (ROE)	-14.47%
Return on Assets (ROA)	-0.98%
Return on Capital (ROIC)	-1.42%
Revenue Per Employee	22.25B
Profits Per Employee	-1.19B
Employee Count	35
Asset Turnover	0.86
Inventory Turnover	4.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.06% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-31.06%
50-Day Moving Average	8,420.60
200-Day Moving Average	9,496.25
Relative Strength Index (RSI)	46.01
Average Volume (20 Days)	5,078

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jeil Pharma Holdings had revenue of KRW 778.79 billion and -41.48 billion in losses. Loss per share was -2,702.00.

Revenue	778.79B
Gross Profit	203.11B
Operating Income	-14.10B
Pretax Income	-59.01B
Net Income	-41.48B
EBITDA	-239.21M
EBIT	-14.10B
Loss Per Share	-2,702.00

Full Income Statement

Balance Sheet

The company has 49.69 billion in cash and 153.31 billion in debt, giving a net cash position of -103.62 billion or -6,750.02 per share.

Cash & Cash Equivalents	49.69B
Total Debt	153.31B
Net Cash	-103.62B
Net Cash Per Share	-6,750.02
Equity (Book Value)	431.94B
Book Value Per Share	21,331.85
Working Capital	4.97B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.72 billion and capital expenditures -4.69 billion, giving a free cash flow of 11.02 billion.

Operating Cash Flow	15.72B
Capital Expenditures	-4.69B
Free Cash Flow	11.02B
FCF Per Share	717.98

Full Cash Flow Statement

Margins

Gross margin is 26.08%, with operating and profit margins of -1.81% and -5.33%.

Gross Margin	26.08%
Operating Margin	-1.81%
Pretax Margin	-7.58%
Profit Margin	-5.33%
EBITDA Margin	-0.03%
EBIT Margin	-1.81%
FCF Margin	1.42%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.63%.

Dividend Per Share	50.00
Dividend Yield	0.63%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	0.63%
Earnings Yield	-34.07%
FCF Yield	9.05%

Dividend Details

Stock Splits

The last stock split was on April 17, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 17, 2006
Split Type	Forward
Split Ratio	10

Scores

Jeil Pharma Holdings has an Altman Z-Score of 1.15. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.15
Piotroski F-Score	n/a